A regional roundtable discussion, moderated by Dr. L. Crain Garrot of Georgia Cancer Specialists, brought together Atlanta-based urologists and oncologists to explore key diagnostic and treatment considerations for metastatic hormone-sensitive prostate cancer (mHSPC). Panelists included Drs. Shailesh Satpute, Yasin Bhanji, Caroline Lu, and Froylan Gonzalez.
Key Discussion Points:
Differentiating Hormone
Role of PSMA PET Scans
Imaging Frequency & Clinical Dilemmas: Monitoring Beyond PSA
Insurance Coverage Issues
Interpreting PSMA PET
In the second segment of a roundtable discussion on metastatic hormone-sensitive prostate cancer (mHSPC), moderated by Dr. L. Crain Garrot, Atlanta-based urologists and oncologists examine the nuanced role of PSMA PET imaging—its advantages, limitations, and clinical application.
Key Discussion Points:
When PSMA PET May Not Be Needed
Limitations of Conventional Imaging in Clinical Trials
Benefits and Pitfalls of PSMA PET
Importance of Clinical Context
Interpreting Small or Ambiguous Lesions
Personalizing mHSPC Treatment
In the third segment of the mHSPC regional roundtable, moderated by Dr. L. Crain Garrot, a panel of Atlanta-based urologists and oncologists reviewed treatment strategies for newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). The discussion centered on interpreting data from major doublet trials and choosing among androgen receptor (AR)-targeted therapies based on individual patient factors.
Key Discussion Points:
Doublet Therapy Trials
Choosing Among Agents
Tolerability and Toxicity
Clinical Practice Trends
Managing Oligometastatic Prostate Cancer Without Lifelong Systemic Therapy
In the fourth segment of the regional roundtable on metastatic hormone-sensitive prostate cancer (mHSPC), moderated by Dr. Crain Garrot, Atlanta-based urologists and oncologists explored the evolving management of oligometastatic prostate cancer, focusing on metastasis-directed therapy (MDT), advanced imaging, systemic therapy de-escalation, and triplet therapy in select patients.
Key Discussion Points:
Role of Metastasis-Directed Therapy (MDT)
Systemic Therapy De-escalation
PSMA PET and Imaging Advances
Risk Stratification & High-Risk Features
Triplet Therapy Considerations
Tailored, Patient-Centric Approach
How Molecular Markers Shape Treatment
This segment of the regional roundtable, moderated by Dr. Crain Garrot, focused on the increasing role of next-generation sequencing (NGS) and genetic testing in the management of metastatic hormone-sensitive prostate cancer (mHSPC). Panelists included urologists and oncologists from Georgia Urology and Georgia Cancer Specialists.
Key Discussion Points:
Genetic & Molecular Testing
Triplet Therapy Considerations
Trial Design & Real-World Practice
Timing of Chemotherapy
Personalized Treatment
Darolutamide & ARANOTE
Moderated by Dr. Crain Garrot, the sixth segment of the prostate cancer roundtable focused on treatment nuances in de novo metastatic prostate cancer and the evolving role of radioligand therapy in castration-resistant disease (CRPC).
Key Discussion Points:
De Novo vs. Metachronous Metastases
Access Challenges with Darolutamide (ARANOTE trial)
Radioligand Therapy – PEACE-3 & PSMAfore Trials
Clinical Decision-Making
PARP Inhibitors for HRR Mutations and mCRPC
In the final segment of the regional roundtable on metastatic hormone-sensitive and castration-resistant prostate cancer, moderated by Dr. Crain Garrot, the panel focused on the early use of PARP inhibitors in metastatic castration-resistant prostate cancer (mCRPC) patients with DNA repair mutations (e.g., BRCA1/2, CHEK2, ATM).
